Fetal toxicity of valsartan and possible reversible adverse side effects
- 20 August 2004
- journal article
- case report
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 70 (8), 547-549
- https://doi.org/10.1002/bdra.20047
Abstract
BACKGROUND Published cases suggest that the use of angiotensin II receptor antagonists is fetotoxic during the third trimester, but not in early pregnancy. CASE: We report a case in which the adverse fetal effect of angiotensin II receptor antagonist treatment was reversed. A woman with chronic hypertension was treated with valsartan until gestation week (GW) 20, when a complete anhydramnios was observed. Six days after interruption of the treatment, amniotic fluid reappeared. It reached a normal level at GW 23.5. The plasmatic creatinine level and the renal ultrasound examination were within normal limits at the six‐month follow‐up. CONCLUSIONS Whereas angiotensin‐II‐receptor antagonist generates a severe renal toxicity, this case suggests that, at least in the first half of pregnancy, these effects can be reversed. Birth Defects Research (Part A) 67:, 2004.Keywords
This publication has 7 references indexed in Scilit:
- Angiotensin II‐receptor‐antagonists: Further evidence of fetotoxicity but not teratogenicityBirth Defects Research Part A: Clinical and Molecular Teratology, 2003
- The safety of valsartan: results of a postmarketing surveillance study on 12 881 patients in EnglandJournal of Human Hypertension, 2002
- Fetal toxic effects and angiotensin-II-receptor antagonistsThe Lancet, 2001
- Fatal Fetal Outcome with the Combined Use of Valsartan and AtenololAnnals of Pharmacotherapy, 2001
- Angiotensin-II-receptor inhibitors in pregnancyThe Lancet, 2001
- Angiotensin-II-receptor inhibitors in pregnancyThe Lancet, 2001
- Losartan and fetal toxic effectsThe Lancet, 2001